Health Care · Electromedical & Electrotherapeutic Apparatus

STXS Stereotaxis, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 1289340106 filings
Russell 2000

STXS at a glance

Stereotaxis, Inc. (STXS, SEC CIK 1289340) filed its latest 10-K annual report on March 12, 2026, a 10-Q quarterly report on November 16, 2026, an 8-K current report on November 10, 2026 and Form 4 insider filings as recently as November 18, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Stereotaxis, Inc. (STXS) reported revenue of $32.4 million (up 20.3% from FY2024) and a net loss of $21.6 million. Diluted EPS was -$0.25.
  • As of September 30, 2026, 18 institutional investment managers tracked by SignalX reported holding Stereotaxis, Inc. (STXS) shares worth $13.2 million in 13F-HR filings.
  • The most recent insider open-market purchase reported on Form 4 was by Menawat Arun Swarup on November 17, 2026 of 121,561 shares at $0.82 per share.
  • In the last 90 days, STXS insiders reported 4 open-market purchases ($136K) and 0 open-market sales ($0) on Form 4, a net purchase of $136K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$32.4M
+20.3% vs prior year
Insiders · 90 days
4 buys · 0 sells
Net +$136K
13F holders
18 funds
$13.2M · −2 vs prior quarter
Latest 8-K
Nov 10, 2026
Item 2.02 · Item 2.03 · Item 3.02 · Item 1.01

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • Robocath acquisition: supplemental risk factors added in Exhibit 99.1 to July 15, 2026 Form 8-K
  • No material changes to previously disclosed 2025 Form 10-K risks outside the acquisition-related supplement

Management Discussion & Analysis

  • Q3 revenue $8.9M, up 20% YoY from $7.5M, driven by systems revenue rising to $3.0M from $1.9M
  • Overall gross margin 44% vs 55% YoY, with disposables, service and accessories margin 59% vs 67%
  • Best performer: systems revenue up to $3.0M from $1.9M; weakest margin: disposables, service and accessories, down to 59% from 67%
  • Cash $4.0M at September 30; operating cash use $11.3M, investing cash use $4.2M, financing cash inflow $6.0M
  • Outlook: additional 2026 losses expected; tariff uncertainty, hospital spending delays and supply-chain disruptions remain headwinds

AI summary of the STXS 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 10, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 financial results announced by Stereotaxis on November 10, 2026
  • Full results and management commentary available in Exhibit 99.1, the earnings press release

Item 2.03: Creation of a Direct Financial Obligation

  • Item 2.03 confirms new indebtedness through the Notes referenced under Item 1.01
  • Debt terms, principal amount, interest rate, maturity and use of proceeds require review of Item 1.01

Item 3.02: Unregistered Sales of Equity Securities

  • Private issuance of Notes and related shares under the Note Financing, outside a public offering
  • Financing completion and additional draws remain subject to required regulatory approvals

Item EX-99.2: Item EX-99.2

  • Up to $24 million convertible financing: $12 million upfront plus $12 million available after regulatory milestones
  • 10% annual interest, accrued until maturity in three years, increasing future cash obligations

Item 1.01: Entry into a Material Definitive Agreement

  • $12.0M initial convertible note financing closed, with potential additional proceeds up to $12.0M
  • Notes carry 10% annual interest, mature November 9, 2029, and generally defer interest through payment-in-kind accrual

Item EX-99.1: Item EX-99.1

  • Q3 revenue $8.9M, up 20% year over year and 16% sequentially, led by system revenue growth to $3.0M
  • Recurring revenue $5.9M, up 6% year over year but down 4% sequentially amid catheter supply constraints
Filed Aug 11, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Q2 revenue $7.7M, down from $8.8M, as system revenue fell to $1.5M from $3.0M
  • Recurring revenue rose to $6.2M, with robotic catheter revenue exceeding $1M and growing 270% sequentially

Item 2.02: Results of Operations and Financial Condition

  • Stereotaxis announced fiscal 2026 second-quarter financial results on August 11, 2026
  • Detailed results and management commentary are contained in Exhibit 99.1, the Earnings Press Release
Filed Jul 16, 2026Full analysis →

Item 8.01: Other Events

  • Acquisition closed July 7, 2026, giving Stereotaxis 100% of Robocath’s shares and voting power
  • Robocath transaction expands Stereotaxis’ ownership and operating exposure to the French medical-technology business

Item EX-99.1: Item EX-99.1

  • Robocath acquisition expected to increase near-term operating losses and negative cash flow, requiring potential funding of its operations
  • $1.1 million in pre-closing operating loans repaid at closing, reducing stock consideration paid to Robocath equityholders

AI summaries of STXS 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for STXS

Don't miss the next STXS filing

  • Alerts as it files. A push when STXS files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut STXS, by share count.
  • Ask anything. An AI agent that reads every STXS filing and answers with sources.

STXS alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Menawat Arun SwarupBuyNov 17, 2026$0.82
Isaac Paul JBuyNov 17, 2026$0.80
Benfer DavidBuyNov 17, 2026$0.83
Isaac Paul JBuyNov 16, 2026$0.82
Fischel NathanBuyNov 9, 2026-
DAFNA Capital Management LLCBuyNov 9, 2026-
Benfer DavidAJul 1, 2026-
Curet MyriamAJul 1, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$26.9M$32.4M
Gross Profit$14.9M$14.6M$17.1M
Operating Income--$24.7M-$22.1M
Net Income-$20.7M-$24.0M-$21.6M
Gross Margin-54.2%52.7%
Op. Margin--91.9%-68.3%
Net Margin--89.3%-66.8%
Balance Sheet
Total Assets$41.9M$46.7M$52.3M
Equity-$6.1M$13.5M
ROE--395.5%-160.5%
Per Share
EPS$-0.27$-0.30$-0.25
Cash Flow
Operating CF--$8.5M-$13.7M

Source: XBRL data in Stereotaxis, Inc. (STXS)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate STXS share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
STXS shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202618$13.2M
Q2 202620$18.9M
Q1 202620$18.8M
Q4 202521$24.5M
Q3 202520$32.6M
Q2 202519$19.9M
Q1 202518$10.5M
Q4 202412$12.8M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
None this quarter.
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 148 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

STXS filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 18, 2026--
4Nov 18, 2026--
4Nov 18, 2026--
10-QNov 16, 2026Analysis
4Nov 12, 2026--
4Nov 12, 2026--
8-KNov 10, 2026Analysis-
SC 13GAug 19, 2026-
10-QAug 12, 2026Analysis
8-KAug 11, 2026Analysis-
8-KJul 16, 2026Analysis-
8-KJul 9, 2026Analysis-
4Jul 1, 2026--
4Jul 1, 2026--
4Jul 1, 2026--
4Jul 1, 2026--
4Jul 1, 2026--
4Jul 1, 2026--
8-KMay 15, 2026Analysis
10-QMay 13, 2026Analysis
8-KMay 12, 2026Analysis
8-KApr 15, 2026Analysis-
4Apr 13, 2026--
10-KMar 12, 2026-
8-KMar 9, 2026Analysis-

Related Health Care companies

All Health Care →

STXS SEC filings: frequently asked questions

Are STXS insiders buying or selling?

In the last 90 days, Stereotaxis, Inc. (STXS) officers, directors and 10% owners reported 4 open-market purchases worth $135,754 by 3 insiders and no open-market sales on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold STXS stock?

As of September 30, 2026, the largest Stereotaxis, Inc. (STXS) holders among the 13F filers tracked by SignalX were BlackRock ($5.4 million), Vanguard Capital Management LLC ($3.7 million), State Street Corp ($1.1 million), Northern Trust ($692,000), Vanguard Portfolio Management LLC ($588,000). 13F-HR reports are filed up to 45 days after each quarter ends.

What was STXS's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Stereotaxis, Inc. (STXS) reported revenue of $32.4 million (up 20.3% from FY2024) and a net loss of $21.6 million. Diluted EPS was -$0.25. The figures come from the XBRL data in the 10-K.

What did STXS report in its latest 8-K?

Stereotaxis, Inc. (STXS) filed an 8-K on November 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 2.03 (Creation of a Direct Financial Obligation), Item 3.02 (Unregistered Sales of Equity Securities) and Item 1.01 (Entry into a Material Definitive Agreement). Q3 2026 financial results announced by Stereotaxis on November 10, 2026.

What are the latest STXS SEC filings?

Stereotaxis, Inc. (STXS) filed its latest 10-K annual report on March 12, 2026, a 10-Q quarterly report on November 16, 2026, an 8-K current report on November 10, 2026 and a Form 4 insider filing on November 18, 2026.

What is STXS's SEC CIK number?

Stereotaxis, Inc. (STXS)'s SEC Central Index Key (CIK) is 1289340. EDGAR lists every STXS filing under that number.

Ask anything about STXS

The research agent reads STXS's filings, financials, insider trades and 13F holders, then answers with sources.